Results 11 to 20 of about 395,238 (233)

Serological evaluation of 52 children immunized with the combined measles, mumps and rubella vaccine

open access: yesThe Turkish Journal of Pediatrics, 1991
Fifty-two of 298 children vaccinated with the measles-mumps-rubella (MMR) vaccine at around the age of 16 months were evaluated for antibody titres against measles, mumps, and rubella.
B Topal, G Kanra, M Ceyhan
doaj   +3 more sources

Economic analyses of rubella and rubella vaccines: a global review

open access: yesBulletin of the World Health Organization, 2002
OBJECTIVE: To investigate whether the incorporation of rubella vaccine into immunization programmes in developing countries is economically justified. METHODS: A MEDLINE search was conducted for articles published between 1970 and 2000 that dealt with ...
Hinman Alan R.   +3 more
doaj   +1 more source

Preclinical study of safety and immunogenicity of combined rubella and human papillomavirus vaccines: Towards enhancing vaccination uptake rates in developing countries

open access: yesPapillomavirus Research, 2019
Rubella vaccine was not part of national immunization programs (NIP) in several countries in the Middle East and North Africa (MENA), South-East Asia (SEA), and South Africa regions until the year 2000.
Asmaa Gohar   +3 more
doaj   +1 more source

Sero-epidemiology of rubella in the urban population of Addis Ababa Ethiopia [PDF]

open access: yes, 2000
We conducted a community-based cluster sample survey of rubella sero-epidemiology in Addis Ababa, Ethiopia in 1994. Among 4666 individuals for whom complete data were available, rubella antibody prevalence was 91% (95% confidence interval: 90, 92).
Nigatu, Wondatir   +6 more
core   +1 more source

Rubella IgM epidemiology in the pre-rubella vaccination era in Uganda

open access: yesBMC Infectious Diseases, 2020
Background Control of Rubella and Congenital Rubella Syndrome using vaccination has shown great success in the America’s. Uganda is due to introduce the Rubella vaccine however the magnitude of transmission is not well documented.
Fred Bagenda   +4 more
doaj   +1 more source

Biological properties of domestic strain vRub-Ant of rubella virus

open access: yesЖурнал микробиологии, эпидемиологии и иммунобиологии, 2022
Introduction. Rubella is a mild infectious disease affecting mainly children and is caused by the rubella virus, part of the Matonoviridae family, genus Rubivirus.
Firaya G. Nagieva   +8 more
doaj   +1 more source

Reliability of medical students' vaccination histories for immunisable diseases [PDF]

open access: yes, 2008
Background Medical students come into contact with infectious diseases early on their career. Immunity against vaccine-preventable diseases is therefore vital for both medical students and the patients with whom they come into contact.
René Gottschalk   +11 more
core   +2 more sources

Measles elimination: progress, challenges and implications for rubella control. [PDF]

open access: yes, 2013
Measles and rubella are major vaccine-preventable causes of child mortality and disability. They have been eliminated from the Americas and some other regions have also come close to elimination.
Lessler, Justin   +7 more
core   +1 more source

A case-control study of autism and mumps-measles-rubella vaccination using the general practice research database: design and methodology. [PDF]

open access: yes, 2001
BACKGROUND: An association between mumps-measles-rubella (MMR) vaccination and the onset of symptoms typical of autism has recently been suggested. This has led to considerable concern about the safety of the vaccine.
Andrew J Hall   +17 more
core   +2 more sources

Evaluation of nationwide supplementary immunization in Lao People's Democratic Republic: Population-based seroprevalence survey of anti-measles and anti-rubella IgG in children and adults, mathematical modelling and a stability testing of the vaccine.

open access: yesPLoS ONE, 2018
BackgroundMeasles outbreaks have occurred in some countries despite supplementary immunization activities (SIA) using measles-containing vaccine with high vaccination coverage.
Masahiko Hachiya   +15 more
doaj   +1 more source

Home - About - Disclaimer - Privacy